Takeda PharmaceuticalSee all their emails

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

A real announcement email from Takeda Pharmaceutical. Captured July 16, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies email from Takeda Pharmaceutical screenshot

Captured Announcement

A corporate press release email from Takeda announcing positive Phase 3 clinical trial results for Zasocitinib in psoriasis treatment.

Clean, single-column layout. Logo at top, followed by a branded hero banner with text and image. Main content section features a clear headline, date, and CTA. Footer includes a feedback survey and standard corporate contact information.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.